SHIM
BCAX

Stone House Investment Management’s Bicara Therapeutics BCAX Stock Holding History

Stone House Investment Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$219 Buy
11
+1
+10% +$17 ﹤0.01% 937
2025
Q4 		$168 Buy
+10
New +$171 ﹤0.01% 813

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Stone House Investment Management's BCAX Position: Q1 2026 in Review

Stone House Investment Management increased its Bicara Therapeutics (BCAX) stake by 10% in Q1 2026, buying an estimated $17 and bringing the position to 11 shares worth $219. The position accounts for ﹤0.01% of the portfolio, ranked #937.

Stone House Investment Management first reported a position in BCAX in Q4 2025 and has held it in 2 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Stone House Investment Management held 11 shares of Bicara Therapeutics worth $219 as of Q1 2026.
  • Stone House Investment Management bought 1 Bicara Therapeutics share in Q1 2026, an estimated $17.
  • Bicara Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #937 holding.
  • Stone House Investment Management first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.